Clinical Trials Logo

Liver Cirrhosis clinical trials

View clinical trials related to Liver Cirrhosis.

Filter by:

NCT ID: NCT02068339 Completed - Clinical trials for Non-alcholic Fatty Liver Disease

Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis

Start date: February 2014
Phase: Phase 3
Study type: Interventional

Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1 (S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c. Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.

NCT ID: NCT02060162 Completed - HIV Clinical Trials

Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa

Start date: October 2013
Phase:
Study type: Observational

This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.

NCT ID: NCT02047240 Completed - Liver Cirrhosis Clinical Trials

Renal Function Determination in Patients With Liver Cirrhosis

Start date: April 2013
Phase: N/A
Study type: Observational

We have several ways to appropriately determine renal function in healthy patients and in several diseases, in cirrhotic population we dont have a precise tool that has sufficient precision that reflects glomerular function, although it has been reported that cystatin C, because of its nature could improve diagnostic accuracy to determinate the renal function in this population. The investigators hypothesize that glomerular filtration obtained from cystatin-C-derived formulas are more accurate when compared to creatinine-derived formulas with DTPA-Tc99 (diethylene-triamine-pentaacetate- technetium-99) as gold standard.

NCT ID: NCT02044523 Completed - Hepatitis C Clinical Trials

Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound

ELF
Start date: January 2014
Phase:
Study type: Observational

Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis. The traditional diagnostic approach requires a biopsy for assessing the severity of liver disease prior to therapy. However, liver biopsy has several limitations: cost, sampling error, and procedure-related morbidity and mortality. Considering the high prevalence of viral hepatitis and nonalcoholic fatty liver disease, a condition often associated with obesity and type 2 diabetes, there is an urgent need for noninvasive screening, diagnosis and monitoring strategies of chronic liver disease severity. Our team has the expertise to investigate ultrasound-based and magnetic resonance-based elastographic methods for the noninvasive staging of liver fibrosis. The primary objective of this cross-sectional study is to compare the sensitivity of elastographic methods for detecting histology-determined significant fibrosis. The secondary objectives are to compare the diagnostic accuracy of these elastographic methods and the influence of potential confounders (inflammation, steatosis and iron deposition) on their diagnostic accuracy.

NCT ID: NCT02041780 Completed - Children Clinical Trials

Non Invasive Assessment of Liver Fibrosis in Children: Comparison of ShearWave Elastography, Fibrotest and Liver Biopsy

SHEARWAVE
Start date: November 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if SWE and Fibrotest®/ Fibromax®, alone or associated, are effective methods to assess liver fibrosis in children.

NCT ID: NCT02031913 Completed - Chronic Hepatitis B Clinical Trials

Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD

Start date: January 2013
Phase:
Study type: Observational [Patient Registry]

Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C. However, clinical significance of steatosis and insulin resistance on fibrosis in chronic hepatitis B (CHB) is not well established. The aim was to investigate the relationship between insulin resistance, hepatic steatosis, and fibrosis in patients with CHB.

NCT ID: NCT02028949 Completed - Clinical trials for Unresectable Non-metastatic Hepatocellular Carcinoma

Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study

Start date: November 22, 2012
Phase: Phase 1
Study type: Interventional

Unresectable, non-metastatic cirrhosis-related hepatocellular carcinoma (HCC) has a poor prognosis as there are no recommended curative treatments. Chemoembolisation is the most widely used treatment in these patients, but this technique can prove to be toxic. intrahepatic arterial chemotherapy with lipiodol and idarubicin could be an effective therapeutic approach, without deteriorating liver function. The rationale for this treatment can be resumed as follows: - HCC are vascularised via the hepatic artery system - The IHA perfusion of anthracyclines leads to high elimination via the liver with low systemic concentrations - The absence of embolisation reduces toxicity - the toxiciity profile of idarubicin is well known and the drug is widely used for the IV treatment of leukemia - idarubicin is the most cytotoxic drug for tumor cell lines. - The in vitro cytotoxicity of idarubicin is 100% at low concentrations - Lipiodol can stay in contact with tumor tissue for several weeks after injection and act as a vector for the drug - The idarubicin-lipiodol is more stable than lipidol emulsions usually given by intraarterial injection - The emulsion is more stable with idarubicin than with other anticancer molecules - Sequential inclusion in accordance with the "continual reassessment method" makes it possible to increase inclusions at a target toxicity level while reducing inclusions at doses that are too low or too toxic The aim of the treatment is to improve survival.

NCT ID: NCT02026401 Completed - Clinical trials for Primary Biliary Cirrhosis

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Start date: February 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.

NCT ID: NCT02024347 Completed - Liver Cirrhosis Clinical Trials

A New Screening Strategy for Varices

LSSM-RCT
Start date: July 2013
Phase: N/A
Study type: Observational

Liver cirrhosis is an advanced stage of chronic liver diseases, which is often associated with various complications, namely esophageal and/or gastric varices, ascites, hepatocellular carcinoma (HCC). It is well known that the risk of complications varies even among cirrhotic patients, as those with more advanced disease would have more complications and poorer survival rates. Liver stiffness measurement (LSM) with transient elastography is found useful to identify cirrhotic patients with higher risk of portal hypertension and presence of varices . Recently, spleen stiffness measurement (SSM) with the same machine was found accurate to predict portal hypertension and esophageal varices. Investigators hypothesized that a new screening strategy guided by LSM and SSM (LSSM) values (LSSM-guided) is non-inferior to conventional strategy in terms of detection rate of clinically significant esophageal and/or gastric varices for patients with liver cirrhosis in an open-labeled randomized controlled trial. Consecutive patients with compensated liver cirrhosis will be invited for the study. Patients fulfilling the study criteria will be randomized into LSSM arm (upper endoscopy only performed to patients with high LSM or SSM values), and control arm (upper endoscopy performed to all patients). Patients randomized into LSSM arm will undergo transient elastography examination; those with high LSM or SSM results will be referred for upper endoscopy examination for to screen varices. Patients randomized into control arm will be directly referred for upper endoscopy examination.

NCT ID: NCT02023229 Completed - Liver Cirrhosis Clinical Trials

Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis

Start date: January 2011
Phase: Phase 4
Study type: Interventional

Malnutrition is a frequent complication in patients with liver cirrhosis. Most patients have decreased dietary intake due to ascites, hepatic encephalopathy and pro-inflammatory cytokines. We hypothesized that branched chain aminoacids can improve nutritional status and delay episodes of hepatic encephalopathy